Contents

	Pages
ш List of Tables	rugoo
ω List of Figures	
ω Aim of work 3	
ш Review of literature	
0	_
ever in neutropenic patients	F 4
	Cl
inical features of the neutropenic host	7
	M
anagement of fever in neutropenic patients	21
rophylaxis against infection in neutropenic pediatric patients	P cancer 49
mmunization in neutropenic patients	I 56
©Patient and Methods 60	
Results 65	
Discussion 81	
₪ Summary & recommendation	

Arabic Summary

List of Abbreviations

6MP 6 mercapto purine

ACIP Advisory Committee on Immunization Practices

AIDS Aquried immuno deficiency syndrome

ALL Acute lymphoblastic leukemia

AML Acute myloid leukemia

ANC Absolute neutrophil count

ARA-C Cytarabine

BCG Bacillus Calmette-Guerin vaccine

CBC Complete blood count

CDC Centers for Disease Control and Prevention

CMV Cyto-megalo virus

CYCLO Cyclophosphamid

DOX Doxorubicin

EORTC European Organization for Research and Treatment of

Cancer

FDA Food and drug administration

G-CSF Granulocyte colony stimulating factor

HSV Herps simplex virus

ICU Intensive care unit

IDSA Infectious Diseases Society of America

MIC Minimal inhibitory concentration

MTX Methotraxate

NHL Non hodgkin's lymphoma

PICU Pediatric intensive care unit

PMNs Poly morphic nuclear cells

RSV Respiratory Syncytial Virus

TMP-SMZ Trimethoprim-sulfamethoxazole

VCR Vincristin

List of Tables

Table		Pages
	Bacterial causes of febrile episodes in neutropenic patien	1ts. 7
Table	(2): Factors that favor a low risk for severe infection among p with neutropenia.	oatients
	26	
Table	(3): Demographic features of the studied patients.	65
Table	(4): Demographic features of the studied patients.	65
Table	(5): Residence of the patients. 66	
Table	(6): Admission features of the studied patients.	66
Table	(7): Initial diseases of the studied patients.	68
Table	(8):	

```
Table (9):
            Type of organism in the two studied groups.
       70
Table (10):
            The correlation between the causative organism and outcome.
       70
Table (11):
             Type of chemotherapy in the two studied groups.
       71
Table (12):
             Chemotherapy received prior episode.
       72
Table (13):
             Antifungal types used in the two studied groups.
       73
Table (14):
             Demographic features of the studied patients.
       74
Table (15):
             Demographic features of the studied patients.
       74
Table (16):
             Residence of admitted patients.
       75
Table (17):
             Admission features of the studied patients.
       75
Table (18)
```

Initial diagnosis of admitted patients.

	77
Table	(19):
	Laboratory results of the studied patients.
	77
Table	(20):
	Type of organism in the two studied groups.
	78
_ , ,	(0.4)
Table	
	The morbidity of the organisms in the two studied groups
	78
Table	(22):
Table	Type of chemotherapy in the two studied groups.
	78
Table	
. 0.0.0	Clinical presentation upon admission.
	79
Table	(24):
	Antifungal types used in the two studied groups.
	80

List of Figures

Pag	
Figure (1):	
From Practical Algorithms in Pediatric Hematology and Oncology	48
Figure (2):	40
Bactec pediatric culture vials (1-3ml)	61

Figure (3):	
Distribution of sex in the patients according to the outcome 65	
Figure (4):	
Distribution of residences in our patients. 60	6
Figure (5): Duration of nutropenia (days) in the two studied groups classified according to line outcome.	7
Figure (6):	
Antibiotic shift and day 7 fever in the two studied groups classified according to line outcome. 67	
Figure (7): Disease types in the three studied groups classified according to line outcome. 68	(0
Figure (8):	
ICU admission in the two studied groups classified according to line outcome.	9
Figure (9):	
Distribution of <i>Klebsiella</i> or <i>Pseudomonas</i> in the two studied groups classified according to line outcome.	7 1
Figure (10):	

Distribution of received chemotherapy.

```
71
```

Figure (11):

Distribution of received chemotherapy.

72

Figure (12):

Relation of sex in PICU admission.

74

Figure (13):

Distribution of admitted patient's residency.

75

Figure (14):

Duration of nutropenia (days) in the two studied groups classified according to ICU admission.

76

Figure (15):

Antibiotic shift and day 7 fever in the two studied groups classified according to ICU admission.

76

Figure (16):

Disease types in the three studied groups classified according to ICU admission.

78

Figure (17):
Distribution of chemotherapy received prior admission.

79